Healio Rheumatology features HSS rheumatologist Vivian P. Bykerk, BSc, MD, FRCPC in a perspectives video series about JAK inhibitors.

Dr. Bykerk discussed safety and efficacy data on JAK inhibitors presented at the 2020 virtual American College of Rheumatology (ACR) meeting; her position on JAK inhibitors versus biologics if a patient has methotrexate inadequate response (MTXIR); determining between JAK inhibitors for different patients; and areas of future research (e.g., combining a JAK inhibitor with a biologic, developing agents that can safely inhibit more than one pathway and advancing precision medicine approaches).

Watch the videos at Healio.com/news/rheumatology.